SLC1A2 and Alzheimer disease: In Alzheimer’s disease (AD) models, alpha-linolenic acid (ALA), an activator of TREK-1, has been shown to upregulate astrocytic GLT-1 expression, which can reduce the accumulation of glutamate and prevent it from exerting its effects, resulting in the relief from neurotoxicity [11].